s708A(5)(e) Cleansing Notice

1 - 2 13 May 2022 ASX Code: MXC LSE Code: MXC Issue of Shares – Cleansing Notice MGC Pharmaceuticals Ltd (‘MGC Pharma’ or the ‘ Company’) advises that in respect to the following Fully Paid Ordinary Shares ( Shares ) issued by the Company on 13 May 2022 : 1. Deferred Consideration – MediCaNL Inc Acquisition 8,961,574 Shares were allotted as the final tranche of deferred consideration Shares issued to the Vendors of MediCaNL. Details of the transaction can be found in MGC Pharma’s ASX Announcement on 22 April 2021 titled “MGC Pharma to acquire Israeli clinical and medical research company, MediCaNL”. Pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ( Corporations Act ), the Company gives notice in relation to the Shares issued above, that: (a) the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act; (b) at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company; (c) at the date of this N otice, the Company has complied with section 674 of the Corporations Act as it applies to the Company; and (d) at the date of this Notice, there is no information to be disclosed which is “excluded information” as defined in subsection 708A(7) of the Corporations Act that is reasonable for investors and their professional advisors to find in a disclosure document. —Ends— Authorised for release by the Managing Director, for further information please contact: MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.com.au MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 info@mgcpharma.com.au UK Broker – Turner Pope Andy Thacker +44 203 657 0050 info@turnerpope.com UK PR Advisors – Tavistock Tim Pearson/Charles Vivian +44 207 920 3150 mgcpharma@tavistock.co.uk 2 - 2 About MGC Pharma MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phyto medicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytomedicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline. Employing its ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company’s EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour. MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. Follow us through our social media channels